Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults

NCT02741128 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

133

Enrollment

INDUSTRY

Sponsor class

Conditions

Dengue Fever
Dengue Hemorrhagic Fever
Human Immunodeficiency Virus

Interventions

BIOLOGICAL: CYD Dengue Vaccine
BIOLOGICAL: Placebo (NaCl 0.9%) vaccine group

Sponsor

Sanofi Pasteur, a Sanofi Company